-
1
-
-
80052639545
-
Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: A meta-analysis
-
L.S. Elias-Sonnenschein, W. Viechtbauer, and I.H. Ramakers Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis J Neurol Neurosurg Psychiatry 82 2011 1149 1156
-
(2011)
J Neurol Neurosurg Psychiatry
, vol.82
, pp. 1149-1156
-
-
Elias-Sonnenschein, L.S.1
Viechtbauer, W.2
Ramakers, I.H.3
-
2
-
-
84555195438
-
CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: A systematic review and meta-analysis
-
M.V. Holmes, P. Perel, and T. Shah CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis JAMA 306 2011 2704 2714
-
(2011)
JAMA
, vol.306
, pp. 2704-2714
-
-
Holmes, M.V.1
Perel, P.2
Shah, T.3
-
3
-
-
84884179049
-
-
EMA Accessed February 19, 2013
-
EMA. Biomarkers. Available from: http://www.ema.europa.eu/ema/index.jsp? curl=pages/special-topics/general/general-content-000349.jsp. [Accessed February 19, 2013].
-
Biomarkers
-
-
-
4
-
-
84884172891
-
-
FDA. Biomarker Qualification Program. [Accessed February 19, 2013]
-
FDA. Biomarker Qualification Program. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ DrugDevelopmentToolsQualificationProgram/ucm284076.htm. [Accessed February 19, 2013].
-
-
-
-
5
-
-
73349091534
-
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
-
S. Salloway, R. Sperling, and S. Gilman A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease Neurology 73 2009 2061 2070
-
(2009)
Neurology
, vol.73
, pp. 2061-2070
-
-
Salloway, S.1
Sperling, R.2
Gilman, S.3
-
6
-
-
84868516038
-
Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease
-
V. Coric, C.H. van Dyck, and S. Salloway Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease Arch Neurol 69 2012 1430 1440
-
(2012)
Arch Neurol
, vol.69
, pp. 1430-1440
-
-
Coric, V.1
Van Dyck, C.H.2
Salloway, S.3
-
7
-
-
84860447272
-
The epidemiology of Alzheimer's disease: Laying the foundation for drug design, conduct, and analysis of clinical trials
-
K. Yaffe, M. Tocco, and R.C. Petersen The epidemiology of Alzheimer's disease: laying the foundation for drug design, conduct, and analysis of clinical trials Alzheimers Dement 8 2012 237 242
-
(2012)
Alzheimers Dement
, vol.8
, pp. 237-242
-
-
Yaffe, K.1
Tocco, M.2
Petersen, R.C.3
-
8
-
-
77957951112
-
Revising the definition of Alzheimer's disease: A new lexicon
-
B. Dubois, H.H. Feldman, and C. Jacova Revising the definition of Alzheimer's disease: a new lexicon Lancet Neurol 9 2010 1118 1127
-
(2010)
Lancet Neurol
, vol.9
, pp. 1118-1127
-
-
Dubois, B.1
Feldman, H.H.2
Jacova, C.3
-
9
-
-
45749113411
-
Development of screening guidelines and clinical criteria for predementia Alzheimer's disease. The DESCRIPA Study
-
P.J. Visser Development of screening guidelines and clinical criteria for predementia Alzheimer's disease. The DESCRIPA Study Neuroepidemiol 30 2008 254 265
-
(2008)
Neuroepidemiol
, vol.30
, pp. 254-265
-
-
Visser, P.J.1
-
10
-
-
84865507195
-
Injury markers predict time to dementia in subjects with MCI and amyloid pathology
-
I.A. van Rossum, S.J. Vos, and L. Burns Injury markers predict time to dementia in subjects with MCI and amyloid pathology Neurology 79 2012 1809 1816
-
(2012)
Neurology
, vol.79
, pp. 1809-1816
-
-
Van Rossum, I.A.1
Vos, S.J.2
Burns, L.3
-
11
-
-
0037514257
-
Decreased b-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease
-
T. Sunderland, G. Linker, and N. Mirza Decreased b-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease JAMA 289 2003 2094 2103
-
(2003)
JAMA
, vol.289
, pp. 2094-2103
-
-
Sunderland, T.1
Linker, G.2
Mirza, N.3
-
12
-
-
0141738373
-
CSF markers for incipient Alzheimer's disease
-
K. Blennow, and H. Hampel CSF markers for incipient Alzheimer's disease Lancet Neurol 2 2003 605 613
-
(2003)
Lancet Neurol
, vol.2
, pp. 605-613
-
-
Blennow, K.1
Hampel, H.2
-
13
-
-
17044430985
-
CSF biomarkers for mild cognitive impairment and early Alzheimer's disease
-
N. Andreasen, and K. Blennow CSF biomarkers for mild cognitive impairment and early Alzheimer's disease Clin Neurol Neurosurg 107 2005 165 173
-
(2005)
Clin Neurol Neurosurg
, vol.107
, pp. 165-173
-
-
Andreasen, N.1
Blennow, K.2
-
14
-
-
67651204382
-
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment
-
N. Mattson, H. Zetterberg, and O. Hansson CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment JAMA 302 2009 385 393
-
(2009)
JAMA
, vol.302
, pp. 385-393
-
-
Mattson, N.1
Zetterberg, H.2
Hansson, O.3
-
15
-
-
74149089257
-
Evaluation of plasma Ab40 and Ab42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment
-
O. Hansson, H. Zetterberg, and E. Vanmechelen Evaluation of plasma Ab40 and Ab42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment Neurobiol Aging 31 2010 357 367
-
(2010)
Neurobiol Aging
, vol.31
, pp. 357-367
-
-
Hansson, O.1
Zetterberg, H.2
Vanmechelen, E.3
-
16
-
-
34547890294
-
CSF tau Ab42 ratio for increased risk of mild cognitive impairment: A follow-up study
-
G. Li, I. Sokal, and J.F. Quinn CSF tau Ab42 ratio for increased risk of mild cognitive impairment: a follow-up study Neurology 69 2007 631 639
-
(2007)
Neurology
, vol.69
, pp. 631-639
-
-
Li, G.1
Sokal, I.2
Quinn, J.F.3
-
17
-
-
53849132759
-
PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment
-
J. Koivunen, T. Pirttila, and N. Kemppainen PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment Dement Geriatr Cogn Disord 26 2008 378 383
-
(2008)
Dement Geriatr Cogn Disord
, vol.26
, pp. 378-383
-
-
Koivunen, J.1
Pirttila, T.2
Kemppainen, N.3
-
18
-
-
84876364640
-
Screening for predementia AD: Time-dependent operating characteristics of episodic memory tests
-
C.A. Derby, L.C. Burns, and C. Wang Screening for predementia AD: time-dependent operating characteristics of episodic memory tests Neurology 80 2013 1307 1314
-
(2013)
Neurology
, vol.80
, pp. 1307-1314
-
-
Derby, C.A.1
Burns, L.C.2
Wang, C.3
-
19
-
-
84855609188
-
Impact of early intervention and disease modification in patients with predementia Alzheimer's disease: A Markov model simulation
-
D. Budd, L.C. Burns, and Z. Guo Impact of early intervention and disease modification in patients with predementia Alzheimer's disease: a Markov model simulation Clinicoecon Outcomes Res 3 2011 189 195
-
(2011)
Clinicoecon Outcomes Res
, vol.3
, pp. 189-195
-
-
Budd, D.1
Burns, L.C.2
Guo, Z.3
-
20
-
-
70349548852
-
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
-
V. Suppiah, M. Moldovan, and G. Ahlenstiel IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy Nat Genet 41 2009 1100 1104
-
(2009)
Nat Genet
, vol.41
, pp. 1100-1104
-
-
Suppiah, V.1
Moldovan, M.2
Ahlenstiel, G.3
-
21
-
-
70349533037
-
Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C
-
Y. Tanaka, N. Nishida, and M. Sugiyama Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C Nat Genet 4 2009 1105 1109
-
(2009)
Nat Genet
, vol.4
, pp. 1105-1109
-
-
Tanaka, Y.1
Nishida, N.2
Sugiyama, M.3
-
22
-
-
38649090347
-
Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial
-
A. Mangia, N. Minerva, and D. Bacca Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial Hepatology 47 2008 43 50
-
(2008)
Hepatology
, vol.47
, pp. 43-50
-
-
Mangia, A.1
Minerva, N.2
Bacca, D.3
-
23
-
-
33646590308
-
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy
-
D.M. Jensen, T.R. Morgan, and P. Marcellin Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy Hepatology 43 2006 954 960
-
(2006)
Hepatology
, vol.43
, pp. 954-960
-
-
Jensen, D.M.1
Morgan, T.R.2
Marcellin, P.3
-
24
-
-
23244457832
-
Peginterferon-α-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C
-
M. von Wagner, M. Huber, and T. Berg Peginterferon-α-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C Gastroenterology 129 2005 522 527
-
(2005)
Gastroenterology
, vol.129
, pp. 522-527
-
-
Von Wagner, M.1
Huber, M.2
Berg, T.3
-
25
-
-
34250320980
-
Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin
-
J.W. Yu, G.Q. Wang, and L.J. Sun Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin J Gastroenterol Hepatol 22 2007 832 836
-
(2007)
J Gastroenterol Hepatol
, vol.22
, pp. 832-836
-
-
Yu, J.W.1
Wang, G.Q.2
Sun, L.J.3
-
26
-
-
23444460553
-
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
-
P. Ferenci, M.W. Fried, and M.L. Shiffman Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin J Hepatol 43 2005 425 433
-
(2005)
J Hepatol
, vol.43
, pp. 425-433
-
-
Ferenci, P.1
Fried, M.W.2
Shiffman, M.L.3
-
27
-
-
84873427421
-
Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model
-
P. McEwan, R. Kim, and Y. Yuan Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model Appl Health Econ Health Policy 11 2013 53 63
-
(2013)
Appl Health Econ Health Policy
, vol.11
, pp. 53-63
-
-
McEwan, P.1
Kim, R.2
Yuan, Y.3
-
28
-
-
60849097257
-
Estimation of the warfarin dose with clinical and pharmacogenetic data
-
International Warfarin Pharmacogenetics Consortium
-
International Warfarin Pharmacogenetics Consortium T.E. Klein, and R.B. Altman Estimation of the warfarin dose with clinical and pharmacogenetic data N Engl J Med 360 2009 753 764
-
(2009)
N Engl J Med
, vol.360
, pp. 753-764
-
-
Klein, T.E.1
Altman, R.B.2
-
29
-
-
47949086046
-
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin
-
B.F. Gage, C. Eby, and J.A. Johnson Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin Clin Pharmacol Ther 84 2008 326 331
-
(2008)
Clin Pharmacol Ther
, vol.84
, pp. 326-331
-
-
Gage, B.F.1
Eby, C.2
Johnson, J.A.3
-
30
-
-
33947227273
-
Association of warfarin dose with genes involved in its action and metabolism
-
M. Wadelius, L.Y. Chen, and N. Eriksson Association of warfarin dose with genes involved in its action and metabolism Hum Genet 121 2007 23 34
-
(2007)
Hum Genet
, vol.121
, pp. 23-34
-
-
Wadelius, M.1
Chen, L.Y.2
Eriksson, N.3
-
31
-
-
59649117935
-
The largest prospective warfarin-treated cohort supports genetic forecasting
-
M. Wadelius, L.Y. Chen, and J.D. Lindh The largest prospective warfarin-treated cohort supports genetic forecasting Blood 113 2009 784 792
-
(2009)
Blood
, vol.113
, pp. 784-792
-
-
Wadelius, M.1
Chen, L.Y.2
Lindh, J.D.3
-
32
-
-
77953304931
-
Warfarin genotyping reduces hospitalization rates: Results from the MM-WES (Medco-Mayo Warfarin Effectiveness study)
-
R.S. Epstein, T.P. Moyer, and R.E. Aubert Warfarin genotyping reduces hospitalization rates: results from the MM-WES (Medco-Mayo Warfarin Effectiveness study) J Am Coll Cardiol 55 2010 2804 2812
-
(2010)
J Am Coll Cardiol
, vol.55
, pp. 2804-2812
-
-
Epstein, R.S.1
Moyer, T.P.2
Aubert, R.E.3
-
33
-
-
84884196169
-
-
Center for Medicare & Medicaid Services Accessed February 19, 2013
-
Center for Medicare & Medicaid Services. National coverage determination for pharmacogenomic testing for warfarin response. Available from: http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId= 333&ncdver=1&bc=BAAAgAAAAAAA&. [Accessed February 19, 2013].
-
National Coverage Determination for Pharmacogenomic Testing for Warfarin Response
-
-
-
34
-
-
73949124118
-
Personalized medicine: Factors influencing reimbursement
-
L.M. Meckley, and P.J. Neumann Personalized medicine: factors influencing reimbursement Health Policy 94 2010 91 100
-
(2010)
Health Policy
, vol.94
, pp. 91-100
-
-
Meckley, L.M.1
Neumann, P.J.2
|